BRIEF-Intensity Therapeutics Highlights 2025 Milestones And Outlines 2026 Strategic Priorities

Reuters01-13

BRIEF-Intensity <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Highlights 2025 Milestones And Outlines 2026 Strategic Priorities

Jan 13 (Reuters) - Intensity Therapeutics Inc INTS.O:

INTENSITY THERAPEUTICS HIGHLIGHTS 2025 MILESTONES AND OUTLINES 2026 STRATEGIC PRIORITIES
INTENSITY THERAPEUTICS INC - PLANS TO FILE PROTOCOL AMENDMENT FOR INVINCIBLE-4 STUDY AND REINITIATE ENROLLMENT IN Q1 2026
INTENSITY THERAPEUTICS INC: TO RAISE ADDITIONAL CAPITAL DURING 2026 TO REINITIATE PATIENT ENROLLMENT AND SITE ACTIVATIONS IN INVICIBLE-3 STUDY

Source text: ID:nPn5bd1b2a

Further company coverage: INTS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603681119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 20:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603681119","market":"fut","top_or_hot":-1,"title":"BRIEF-Intensity Therapeutics Highlights 2025 Milestones And Outlines 2026 Strategic Priorities","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Highlights 2025 Milestones And Outlines 2026 Strategic Priorities</title></head><body><p><span>Jan 13 (Reuters)</span><span> - </span>Intensity Therapeutics Inc <span>INTS.O</span>:</p><ul><li><p>INTENSITY THERAPEUTICS HIGHLIGHTS 2025 MILESTONES AND OUTLINES 2026 STRATEGIC PRIORITIES</p></li><li><p>INTENSITY THERAPEUTICS INC - PLANS TO FILE PROTOCOL AMENDMENT FOR INVINCIBLE-4 STUDY AND REINITIATE ENROLLMENT IN Q1 2026</p></li><li><p>INTENSITY THERAPEUTICS INC: TO RAISE ADDITIONAL CAPITAL DURING 2026 TO REINITIATE PATIENT ENROLLMENT AND SITE ACTIVATIONS IN INVICIBLE-3 STUDY</p></li></ul><p>Source text: <span>ID:nPn5bd1b2a</span></p><p>Further company coverage: <span>INTS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Intensity Therapeutics Highlights 2025 Milestones And Outlines 2026 Strategic Priorities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Intensity Therapeutics Highlights 2025 Milestones And Outlines 2026 Strategic Priorities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 20:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Highlights 2025 Milestones And Outlines 2026 Strategic Priorities</title></head><body><p><span>Jan 13 (Reuters)</span><span> - </span>Intensity Therapeutics Inc <span>INTS.O</span>:</p><ul><li><p>INTENSITY THERAPEUTICS HIGHLIGHTS 2025 MILESTONES AND OUTLINES 2026 STRATEGIC PRIORITIES</p></li><li><p>INTENSITY THERAPEUTICS INC - PLANS TO FILE PROTOCOL AMENDMENT FOR INVINCIBLE-4 STUDY AND REINITIATE ENROLLMENT IN Q1 2026</p></li><li><p>INTENSITY THERAPEUTICS INC: TO RAISE ADDITIONAL CAPITAL DURING 2026 TO REINITIATE PATIENT ENROLLMENT AND SITE ACTIVATIONS IN INVICIBLE-3 STUDY</p></li></ul><p>Source text: <span>ID:nPn5bd1b2a</span></p><p>Further company coverage: <span>INTS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INTS","symbol_name":"Intensity Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA2RJJTD:1","article_id":"2603681119","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603681119","pubTimestamp":1768308876,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Intensity Therapeutics Highlights 2025 Milestones And Outlines 2026 Strategic PrioritiesJan 13 (Reuters) - Intensity Therapeutics Inc INTS.O:INTENSITY THERAPEUTICS HIGHLIGHTS 2025 MILESTONES AND","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INTS":"Intensity Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Intensity Therapeutics重点介绍2025年里程碑并概述2026年战略重点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INTS":0.9},"content_text":"BRIEF-Intensity Therapeutics Highlights 2025 Milestones And Outlines 2026 Strategic PrioritiesJan 13 (Reuters) - Intensity Therapeutics Inc INTS.O:INTENSITY THERAPEUTICS HIGHLIGHTS 2025 MILESTONES AND OUTLINES 2026 STRATEGIC PRIORITIESINTENSITY THERAPEUTICS INC - PLANS TO FILE PROTOCOL AMENDMENT FOR INVINCIBLE-4 STUDY AND REINITIATE ENROLLMENT IN Q1 2026INTENSITY THERAPEUTICS INC: TO RAISE ADDITIONAL CAPITAL DURING 2026 TO REINITIATE PATIENT ENROLLMENT AND SITE ACTIVATIONS IN INVICIBLE-3 STUDYSource text: ID:nPn5bd1b2aFurther company coverage: INTS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,event","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603681119","isCrawlerRequest":true}